The effects of equipotent glucose-lowering doses of insulinlike growth factor I (IGF-I) and insulin on tracerdetermined glucose kinetics and several metabolites were compared in 14 experiments (7 in each group) in fasted, totally depancreatized dogs. This model prevented variations in insulin secretion induced by IGF-I and permitted evaluation of the effects of IGF-I on extrapancreatic glucagon. Steady-state moderate hyperglycemia (9.9 ± 0.2 mM) was maintained by a subbasal intraportal infusion of insulin (1.29 ± 0.17 pmol • kg~1 • min~1). This was continued throughout the experiment, allowing evaluation of IGF-I effects on insulin clearance. Human recombinant IGF-I or insulin was given intravenously as a primed infusion for 90 min, followed by a 50-min recovery period. The dose of IGF-I was a 2.6-nmol/kg bolus plus 57.4 pmol • k g 1 • min 1 . The insulin dose required to induce the same plasma glucose decline as IGF-I (44 ± 6 vs. 43 ± 5%, NS) was 9-12 times lower (0.06-nmol/kg bolus + 6.4 ± 0.6 pmol • k g 1 • min~1). However, the mechanism of this decline differed with IGF-I and insulin; glucose production was much less suppressed (25 ± 9 vs. 42 ± 11%, P < 0.001) and glucose utilization was more stimulated (68 ± 18 vs. 38 ± 19%, P < 0.05) with IGF-I. Lactate and pyruvate increased significantly with IGF-I (by 85 ± 28 and 123 ± 83%, respectively) but not with insulin. Glycerol and freefatty acid levels decreased much less with IGF-I than insulin (29 ± 16 vs. 52 ± 5%, P < 0.05, and 36 ± 10 vs. 56 ± 8%, P < 0.01). p-Hydroxybutyrate, alanine, and glucagon decreased similarly with IGF-I or insulin by 60, 20, and 20%, respectively. Plasma insulin was not affected by IGF-I administration (92.6 ± 8.5 vs. 92.6 ± 10.1 pM). In conclusion, in insulin-infused depancreatized dogs, 1) IGF-I is 8-11% as potent as insulin as a glucose-lowering agent on a molar basis, 2) IGF-I does not affect insulin clearance at doses effective in lowering plasma glucose, and 3) equipotent glucose-lowering doses of IGF-I and insulin have very different effects on both glucose kinetics and lipolysis. This suggests that the IGF-l-insulin potency ratio in vivo is higher in muscle than liver or adipose tissue. Therefore, insulinlike effects of supraphysiological doses of IGF-I can be mediated not only through the insulin but also the IGF-I receptor.
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potency ratio in vivo is higher in muscle than liver or adipose tissue. Therefore, insulinlike effects of supraphysiological doses of IGF-I can be mediated not only through the insulin but also the IGF-I receptor. Diabetes 39:340-47, 1990 I nsulinlike growth factor I (IGF-I) is a 7500-M r polypeptide that shares a high degree of sequence homology with insulin and a common tertiary structure with proinsulin (1) . Physiologically, it is involved in the growth and differentiation of cells. As a growth-promoting agent in vitro, it is 50-100 times more potent than insulin (1) . IGF-I is synthesized in many tissues. However, the main source of circulating IGF-I is the liver, which secretes IGF-I continuously. Production of IGF-I is under the control of growth hormone and the overall metabolic status of the organism (1) .
At supraphysiological doses, IGF-I has been found to lower blood glucose in nondiabetic animals and humans (2) (3) (4) (5) (6) . After an intravenous bolus injection, its hypoglycemic potency has been reported to be between 1.5 and 7% that of insulin on a molar basis (2, 3) . In nondiabetic humans, the effects of IGF-I on the counterregulatory hormones have been found to be similar to the effects of insulin of equivalent hypoglycemic potency (3) . IGF-I also decreases free-fatty acid (FFA) levels in nondiabetic rats and humans. However, as an antilipolytic agent, it is less effective than insulin (2, 3) .
Differential metabolic activities of IGF-I and insulin have been demonstrated in vitro in muscle (7, 8) and adipose tissue (9, 10) . IGF-I has a marked effect on glucose uptake in mouse muscle tissue with an IGF-l-insulin potency ratio of from 1:10 to 1:20 (7) . In rat and human adipose tissue, the IGF-I-insulin potency ratio has been reported to be only from 1:50 to 1:100 (9) and 1:600 to 1:1000 (10) .
This study was undertaken 1) to determine the equipotent glucose-lowering doses of IGF-I and insulin in diabetes while avoiding hypoglycemia, 2) to find out whether equipotent glucose-lowering doses of IGF-I and insulin have differential effects on glucose production and utilization and plasma concentrations of metabolic substrates in diabetes, and 3) to determine whether IGF-I affects insulin clearance. Depancreatized dogs were used to differentiate the effects of IGF-I from those related to any variations in insulin secretion. Such variations could occur either from a decrease in plasma glucose levels or as a direct effect of IGF-I (5). In addition, because depancreatized dogs secrete glucagon (M, 3500) from the gastric mucosa (11), the effects of IGF-I and insulin on extrapancreatic glucagon were compared. In the basal period, steady-state moderate hyperglycemia was maintained by infusing insulin intraportally at a fixed subbasal rate. Intraportal administration permitted us to maintain a constant physiological portal-peripheral gradient of insulin, which cannot be achieved in humans. The subbasal intraportal infusion of insulin was continued before and after the peripheral administration of IGF-I or insulin, allowing evaluation of IGF-I effects on insulin clearance.
IGF-I or insulin was administered as a bolus plus continuous infusion. The bolus-infusion ratio was higher with IGF-I. The larger bolus of IGF-I permitted us to saturate quickly the IGF-I-binding proteins, thus preventing insulin levels from plateauing much earlier than IGF-I. An early insulin plateau could lead to misleading differential effects after administration of the two hormones.
RESEARCH DESIGN AND METHODS
Male mongrel dogs weighing 18-28 kg underwent total pancreatectomy performed under general anesthesia induced with pentobarbital sodium and maintained with 0.5-1% halothane in carrier gas containing nitrous oxide (2.5 L/min) and oxygen (3.5 L/min). At surgery, Silastic cannulas were inserted into the aortic arch via the carotid artery for blood sampling, into the superior vena cava through the jugular vein for the infusions of tracer and IGF-I or peripheral insulin (2 cannulas), and into the portal vein through a branch of the splenic vein for the infusion of subbasal insulin. Dogs were fed once daily with a combined diet of 15 g/kg dog chow (Ralston Purina Canada, Mississauga, Ontario) and 500 g beef chunks (Canada Packers, Toronto). Pancreatic enzymes were supplemented (Cotazym, Organon Canada, Toronto). Diabetes was treated with one daily subcutaneous injection of regular and NPH porcine insulin (Lilly, Indianapolis, IN) to maintain glycosuria < 1 % . Mean insulin requirement was 42 ± 5 U. Porcine insulin does not induce the formation of anti-insulin antibodies in dogs for at least 2 mo (12), thus allowing accurate measurements of plasma insulin.
Fourteen experiments were carried out in eight conscious dogs 1-6 wk after pancreatectomy. Insulin was withdrawn for at least 24 h and food withdrawn 18 h before experiments.
The experimental protocol was started with an intraportal insulin infusion of 24 then 12 pmol • kg~1 • min-1 to lower plasma glucose toward moderately hyperglycemic levels (-10 mM). These were subsequently maintained by infusing A. GIACCA AND ASSOCIATES insulin intraportally at a constant subbasal rate (1.29 ±0.17 pmol • kg~1 • min~1) for 2 h before initiation of the peripheral infusion of IGF-I or insulin and throughout the infusion and recovery periods. After plasma glucose decreased to <14 mM, a primed (11.1 x 10 6 Bq) infusion (9.5 x 10 3 Bq/min) of [3- 3 H]glucose (Du Pont-NEN, Lachine, Quebec, Canada) was started and maintained throughout the experiment together with intraportal insulin. After 150 min of tracer equilibration and at least 60 min of steady-state hyperglycemia, human recombinant IGF-I (KabiVitrum, Stockholm) or insulin was administered peripherally through a separate catheter. A glucose-lowering dose of IGF-I was chosen such that hypoglycemic counterregulation could be avoided. This was determined experimentally. The equipotent dose of insulin was also determined experimentally by small adjustments of the insulin dose in different dogs, starting from the dose that corresponds to the IGF-I-insulin ratio previously described in vivo (2,3). IGF-I was administered as a 2.6-nmol/ kg bolus followed by a 57.4-pmol • kg" 1 • min~1 continuous infusion for 90 min, followed by a 50-min recovery period. Insulin was administered as a 0.06-nmol/kg bolus and a 6.4 ± 0.6-pmol • kg- 1 • min" 1 infusion for the same time frame as IGF-I. Arterial blood samples were taken every 10 min from -3 0 to +140 min.
Glucose was analyzed by the glucose oxidase method on a Beckman Glucose Analyzer 2 (Fullerton, CA). Lactate, pyruvate, alanine, glycerol, and p-hydroxybutyrate were determined by a microfluorometric adaptation of standard enzymatic methods with a fluoromicrophotometer (Aminco, Silver Spring, MD). Insulin, glucagon, and FFA were assayed as previously described (13) . Samples for total IGF-I were collected in the last four experiments in which IGF-I was administered, when we had access to the radioimmunoassay. The radioimmunoassay was performed on serum samples extracted with acid-ethanol with a polyclonal antibody (14) . The rates of glucose appearance and disappearance and the plasma clearance rate of glucose were calculated with [3- 3 H]glucose as tracer (15) after smoothing data according to the optimal-segments method (16) . Glucose disappearance corresponded to glucose utilization and plasma clearance rate of glucose corresponded to glucose metabolic clearance rate (MCR) because plasma glucose levels were below the renal threshold for glucose (17) . The activity of [3- 3 H]glucose was measured by liquid-scintillation spectrometry on a Mark III counter (Tracor, Elk Grove Village, IL) after deproteination of the plasma samples with Ba(OH) 2 and ZnSO 4 and evaporation of deproteinate.
Data are expressed as means ± SE. Percentage differences from basal refer to maximum variations. Analysis of variance followed by Tukey's t tests when appropriate was used for comparison between experimental groups (IGF-I and insulin) and among experimental periods (basal, infusion, and recovery) within each group. Calculations were performed with the SAS System (Cary, NC) on an IBM Personal System II (White Plains, NY).
RESULTS
Despite randomization of the experimental sequence and the same treatment in the basal period, basal glucose and glucose production were slightly lower (Figs. 1 and 2), whereas basal insulin was higher in the series of experiments where IGF-I was to be given ( Fig. 3 ). All data except plasma glucose are plotted as differences from basal (A).
Plasma glucose fell from a steady-state value of 9.67 ± 0.22 to 5.49 ± 0.63 mM with IGF-I and from 10.16 ± 0.35 to 5.81 ± 0.55 mM with insulin and remained at normoglycemic levels during the recovery period in both sets of studies (Fig. 1 ). The decline from basal was similar during the administration of both IGF-I and insulin (44.0 ± 5.9 vs. 43.2 ± 5.4%, NS). Figure 3 shows insulin and glucagon concentrations. Basal insulin was kept stable (coefficient of variation 8.5%) by the exogenous intraportal infusion. During IGF-I administration, plasma insulin was unchanged (92.6 ± 8.5 vs. 92.6 ±10.1 pM). With the peripheral infusion of insulin, plasma insulin plateaued at -300 pM, returning promptly to basal in the recovery period. Glucagon decreased by 18.9 ± 6.5% with IGF-I and by 20.6 ± 12.7% with insulin with no significant difference between the two. One glucagon value was >3SD higher than the general mean and was therefore not included. Exclusion or inclusion of this outlier did not alter the result of the comparison between the two groups.
In Fig. 4 , total IGF-I levels are shown. IGF-I increased from 40.8 ± 6.0 to 72.2 ± 13.2 nM, plateauing at the same time as insulin but remaining moderately elevated during the recovery period. Figure 2 shows the parameters of glucose kinetics. There was a sustained decrease in glucose production (P. a ) of 24.9 ± 9.4% with IGF-I versus 41.8 ± 11.0% with insulin. This decline was considerably less with IGF-I (P < 0.001). Glucose utilization (ft d ) increased transiently by 68.0 ± 17.9% with IGF-I and only by 37.7 ± 19.3% with insulin. The increase was significantly greater with IGF-I (P < 0.05). The rise in glucose MCR was sustained: 122.3 ±35.7% with IGF-I and 103.7 ± 51.3% with insulin (P < 0.01). R a , R ti , and MCR remained significantly higher throughout the recovery period in the IGF-I studies, and R a and MCR appeared to return more rapidly toward basal values after withdrawal of insulin than IGF-I infusion.
As shown in Fig. 5 , we found a positive correlation between glucose clearance and production in both sets of experiments. This indicates that the decline in plasma glucose induced by the rise in clearance had a stimulatory effect on glucose production, which partially counteracted the suppressive effect of IGF-I or insulin. Seven experiments were performed in each group. One glucagon value in insulin group was not included because it was >3 SD higher than general mean. Significance levels refer to differences between IGF-I and insulin administration in infusion and recovery periods. Significant variations from basal values within each group are described in text.
As shown in Fig. 6 , lactate rose by 85.0 ± 28.2% with IGF-I, declining before the end of the infusion. With insulin, there was no significant change. The difference in lactate during IGF-I and insulin administrations was highly significant (P < 0.001). Similar to lactate, pyruvate increased by 122.9 ± 82.5% with IGF-I, whereas with insulin the increase was not significant. We found a positive correlation between glucose utilization and lactate or pyruvate levels during insulin but not during IGF-I administration (Fig. 7) . Alanine decreased by 20.2 ± 9.3% with insulin and by 20.9 ± 4.97% with IGF-I during the infusion period with no significant difference in the IGF-I and insulin experiments. These declines continued in the recovery period. Figure 8 shows the parameters of lipid metabolism. Glycerol decreased by 29.4 ± 15.5% with IGF-I and by 52.1 ± 5.0% with insulin, and the decrease with insulin was significantly greater (P < 0.05). FFA levels decreased by 35.7 ±10.4 and 56.4 ± 8.0% with IGF-I and insulin, respectively, again to a significantly greater degree with insulin (P < 0.01). p-Hydroxybutyrate decreased by 60.2 ± 13.0% with insulin and by 65.6 ± 6.9% with IGF-I with no difference between the two treatments. Glycerol, FFA, and fi-hydroxybutyrate increased toward basal levels during the recovery period.
DISCUSSION
The acute metabolic effects of IGF-I were evaluated in hyperglycemic insulin-infused depancreatized dogs. This experimental model allowed us to avoid feedback actions of IGF-I on endogenous insulin secretion without performing a pancreatic clamp involving the use of somatostatin. Although most data indicate that somatostatin does not interfere with glucoregulation (18) , it has been reported that under certain conditions, somatostatin may affect glucose clearance (19) and FFA metabolism (13, 20, 22) . Most important, it is not known whether somatostatin interferes with metabolic actions of IGF-I.
To find out the equipotent glucose-lowering doses of IGF-I and insulin, the decline from moderate hyperglycemia to nomnoglycemia obtained with the peripheral administration of IGF-I was mimicked by a peripheral infusion of insulin. This approach, while avoiding hypoglycemia, allowed a more straightforward determination of equipotency than evaluation of glucose requirements during a glucose clamp.
IGF-I was from 8 to 11% as potent as insulin in lowering plasma glucose: 8% on the basis of total and 11% on the basis of infused dose. A large IGF-I bolus was required to lower plasma glucose with IGF-I, consistent with the notion that IGF-I is associated with binding proteins in the circulation and that the insulinlike effects of IGF-I are probably due to its free levels (2,3). The IGF-I-insulin potency ratio reported in this study is in the upper range of previously reported values in nondiabetic animals and humans. Both protein binding and endogenous IGF-I may affect this ratio. In diabetes, low binding of IGF-I to high-molecular-weight protein (22) but increased binding of IGF-I to low-molecularweight protein has been described (23) . In human diabetes, IGF-I levels are normal (24) or low (25) . In depancreatized dogs, IGF-I levels are low (26) but return to normal with insulin administration (26) and/or correction of defective calorie balance (27) . In this study, total basal IGF-I levels were in the normal range. In this study, the subbasal intraportal infusion of insulin kept plasma glucose and insulin levels constant in the basal state. When IGF-I was infused after at least 2 h of constant intraportal insulin infusion, plasma insulin was unaffected. Therefore, at the dose of IGF-I given, there was no effect on insulin clearance. This in vivo finding is in contrast with previous in vitro observations that similar levels of IGF-I inhibit insulin degradation (28) . Because in in vitro experiments IGF-I was not bound, its free concentration was much higher than in our experiments, and it is therefore possible that the difference between our in vivo and in vitro data reflects the large difference in free IGF-I levels.
Despite the facts that the experiments were carried out in random order and the infusion rates were not significantly different, basal insulin levels were slightly higher in the IGF-I than in the insulin experiments. Accordingly, slightly lower glucose concentrations and production were observed. These small basal differences were taken into account in analysis by considering the change of each parameter from its corresponding basal value. Different basal insulinization might induce different sensitivity to the glucose-lowering actions of IGF-I and insulin or alter the response of the liver and the periphery to the two hormones. We feel that in this study, this possibility is unlikely given the small differences in the basal state (slightly higher glucose levels due to higher glucose production and not to lower clearance in the insulin-infusion experiments).
A higher bolus-infusion ratio of IGF-I than insulin was administered to avoid confounding effects related to different kinetics of the two peptides during the infusion period. A plateau of total IGF-I levels was indeed reached at the same time as insulin. However, we cannot rule out differences between the time courses of insulin and free IGF-I levels.
With IGF-I, plasma glucose fell due to a decrease in hepatic glucose production and an increase in glucose utili- zation. Glucose utilization then returned to basal, reflecting a reduced mass-action effect of the declining glucose as evidenced by the sustained increase in MCR. The same decrease in plasma glucose with the peripheral insulin infusion was due to a greater suppression of glucose production than IGF-I and a lesser stimulation of utilization and clearance. The suppression of glucose production was 25% with IGF-I and 42% with insulin, which is much less than generally described during a glucose clamp at similar plasma insulin levels (29) . This indicates that the suppressive effect of IGF-I and insulin on hepatic glucose production was offset in part by the decrease in plasma glucose, as evidenced also by the positive correlation between glucose clearance and production. Therefore, it is important that equipotent glucose-lowering doses of IGF-I and insulin rather than equimolar doses were used, because different slopes in glycemia can confound the evaluation of the differential effects of the two peptides (30, 31) . The positive correlation between glucose clearance and production appears to indicate autoregulation at normoglycemia as being presumably independent of counterregulatory hormones. In fact, glucagon decreased, and we have shown previously that the rise in catecholamines if any is too marginal to be associated with any glucoregulatory effect under such conditions (30) . Most other counterregulatory hormones do not affect glucoregulation acutely. Also, the differential effects on glucose fluxes could not be due to differences in plasma glucagon levels, which declined similarly with both IGF-I and insulin. With regard to catecholamines, there is no evidence that, in addition to the glucose decline (the same in both sets of experiments), insulin or IGF-I directly affects the release of epinephrine or norepinephrine.
The difference between our data and glucose production determined during a glucose clamp might also relate to problems in tracer methodology. It has been reported that under certain conditions, the use of tracers for the determination of glucose kinetics can lead to underestimations of glucose production due to contaminants in the tracer (32, 33) . This assumes more importance under conditions where a near-maximal and/or prolonged rise in glucose utilization occurs, such as during hyperinsulinemic glucose clamps (33, 34) . In our experiments, glucose utilization was increased moderately and only in the early part of the study. Moreover, variations in specific activity were less than with a conventional clamp, which might imply less underestimation of glucose production by the one-compartment fixedpool method for describing glucose kinetics in non-steady state (35, 36) .
With regard to differences in glucose kinetics between IGF-I and insulin, previous studies in nondiabetic rats have shown that IGF-I stimulates glucose uptake, but there have been contradictory reports on its effects on glucose production (4,5). IGF-I had no effect on glucose production in one study (4) . In another study, IGF-I was less effective than insulin in suppressing glucose production, which, however, was shut off at maximal doses of both hormones; glucose uptake by the muscle was not significantly different (5) . Equipotent glucose-lowering doses of IGF-I and insulin were compared only when maximal doses were used (5). At equipotent submaximal glucose-lowering doses, we observed less effects of IGF-I than insulin on glucose production and greater effects on glucose utilization and clearance. The site of this greater utilization cannot be determined by noninvasive tracer methods. However, it is unlikely that the differential effects of the two peptides on glucose utilization are due to effects on the liver and adipose tissue because IGF-I was less effective than insulin on hepatic glucose production and antilipolysis. Muscle is therefore the most likely site for the preferential stimulation in glucose utilization observed with IGF-I. The rise in lactate and pyruvate that occurs with IGF-I but not with insulin is also in keeping with a greater effect of IGF-I on the muscle, a major site of lactate production (37) . Although turnover of lactate and pyruvate was not evaluated in our study, it is likely that IGF-I induced higher production rather than lower hepatic utilization of lactate and pyruvate than did insulin, because the suppression of glucose production was less pronounced with IGF-I. Increased lactate and pyruvate production could be secondary to increased glucose utilization. However, a positive correlation between lactate and pyruvate levels and total glucose utilization was found only with insulin not with IGF-I. It is therefore possible that with IGF-I, a preferential stimulation of glycolysis over other pathways of glucose utilization might account for the increased lactate and pyruvate concentrations. In another study (3), equipotent IGF-I and insulin produced an equivalent rise in lactate in nondiabetic humans, but IGF-I and insulin were injected as an intravenous bolus at approximately twofold higher doses than our total dose (bolus + infusion).
Both glycerol and FFA decreased with IGF-I and insulin, consistent with an antilipolytic effect of the two peptides, in addition to a likely effect on reesterification. Glycerol and FFA levels fell to a lesser extent with IGF-I than with insulin, indicating a less-potent antilipolytic effect. This is in accordance with previous in vivo (2, 3) and in vitro (9, 10) reports. Interestingly, in this study, IGF-I and insulin had similar effects on p-hydroxybutyrate concentrations. This indicates that there may be a threshold FFA level before a change in FFA supply can turn off ketogenesis (38) .
IGF-I decreases proteolysis and reduces amino acid levels, including alanine, in nondiabetic rats (4). However, alanine concentrations reflect glucose and protein metabolism. Because glucose fluxes were different with IGF-I and insulin, the similar decrease in alanine observed in this study does not necessarily imply similar effects of the two hormones on protein metabolism.
During the recovery period, the persistent moderate elevation in total IGF-I levels appears to account for the slower return of some parameters, especially glucose production, toward basal levels. Although the short observation period might have prevented detection of further differences between the two sets of experiments, the time course of recovery was less different than expected on the basis of the half-lives of IGF-I and insulin. This may be explained by the relationship between the insulinlike effects of IGF-I and its free levels.
Differential activity of IGF-I and insulin on insulin target tissues could be explained by interaction with different receptors. IGF-I receptors are present in high concentrations in muscle in mice (7), rats (39) , and humans (40) . In rat and human hepatocytes (41) and adipocytes (42) (43) (44) , the concentration of specific receptors is minimal. In vitro studies on mouse soleus muscle have shown that the effects of IGF-I on glucose transport and metabolism and protein synthesis are first noticeable in a concentration range that inhibits 125 I-IGF-I binding but is too low to affect 125 l-insulin binding (7, 8) . In adipose tissue, IGF-I action requires an intact insulin receptor (42) . There are no data regarding IGF-I receptors in insulin target tissues in the dog. Therefore, it is not clear whether the described effects were mediated by IGF-I or insulin receptors. However, the 1:11 potency ratio between IGF-I and insulin is in the range of the potency ratio determined in vitro for rat muscle tissue. Furthermore, the differential effects of IGF-I and insulin on glucose kinetics (greater effect of IGF-I on glucose utilization, less effect on production) and certain metabolites (excess of lactate, reduced antilipolysis with IGF-I) also suggest that some insulinlike effects of IGF-I in vivo could be mediated not only through the insulin but also through the IGF-I receptor.
